5.1 Controlled Substance Schedules & KY Specific Classifications

5.1 Controlled Substance Schedules & KY Specific Classifications

The Federal Comprehensive Drug Abuse Prevention and Control Act of 1970, commonly known as the Controlled Substances Act (CSA) (codified at Title 21 of the United States Code, 21 U.S.C. § 801 et seq.), establishes a closed regulatory system for the manufacturing, distribution, prescribing, and dispensing of habit-forming, addictive, and diversion-prone medications. In the Commonwealth of Kentucky, the Kentucky Uniform Controlled Substances Act (KRS Chapter 218A) operates concurrently with federal law through administrative regulations promulgated by the Cabinet for Health and Family Services (Title 902 KAR Chapter 55). Under the Stricter Law Rule, whenever Kentucky reclassifies a substance into a more restrictive schedule than federal law, pharmacists must enforce Kentucky's more stringent standard.

Statutory and Regulatory Authorities:

• Federal CSA: Title 21 U.S.C. § 812 (Schedules of Controlled Substances) & 21 CFR Part 1308.
• Kentucky Statutes: KRS 218A.020–218A.130 (Kentucky Scheduling Authority and Criteria).
• Kentucky Administrative Regulations:
  • 902 KAR 55:015 (amended eff. 3-12-2026): Schedules of controlled substances — the single consolidated Kentucky schedule list. It designates gabapentin as C-V; nalbuphine as C-IV; pentazocine, barbital, methylphenobarbital, and phenobarbital as C-III (federal C-IV); and tianeptine as C-I. 902 KAR 55:020, 55:025, 55:030, and 55:035 were repealed by 902 KAR 55:041 — citing them is a stale-source error.
  • 902 KAR 55:045: Exempt prescription products — Kentucky adopts the federal exempt-product list at 21 CFR 1308.32 but carves butalbital out of the exemption.
  • KRS 218A.190: Exempt codeine preparations — Kentucky's non-prescription codeine sale statute.
  • 902 KAR 55:040: Excluded nonnarcotic substances (OTC nonnarcotics excluded from the schedules under 21 U.S.C. 811(g)(1)) — note this regulation has nothing to do with codeine sales.

---

1. Federal CSA Scheduling Framework & Statutory Criteria

The federal CSA categorizes controlled substances into five distinct schedules (Schedules I through V) based upon three core statutory criteria evaluated by the Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA):

1. The substance's actual or relative potential for abuse;
2. The substance's currently accepted medical use in treatment in the United States; and
3. The international and domestic scientific evidence regarding the drug's liability to cause physical dependence or psychological dependence.

┌─────────────────────────────────────────────────────────────────────────────┐
│                     FEDERAL CSA SCHEDULING HIERARCHY                        │
├──────────┬─────────────────┬──────────────────────┬─────────────────────────┤
│ Schedule │ Abuse Potential │ Accepted Medical Use │ Dependence Liability    │
├──────────┼─────────────────┼──────────────────────┼─────────────────────────┤
│ C-I      │ Highest         │ None in the U.S.     │ Severe                  │
│ C-II     │ High            │ Yes (Strict Limits)  │ Severe Physical / Psych │
│ C-III    │ Moderate-to-Low │ Yes                  │ Moderate-Low Physical / │
│          │ (< C-I or C-II) │                      │ High Psychological      │
│ C-IV     │ Low (< C-III)   │ Yes                  │ Limited Physical /      │
│          │                 │                      │ Limited Psychological   │
│ C-V      │ Lowest (< C-IV) │ Yes                  │ Extremely Limited       │
└──────────┴─────────────────┴──────────────────────┴─────────────────────────┘

Detailed Analysis of Schedules I through V Criteria (21 U.S.C. § 812)

Schedule I (C-I)

• Statutory Finding: The drug or substance has a high potential for abuse, has no currently accepted medical use in treatment in the United States, and lacks accepted safety for use under medical supervision.
• Representative Substances: Heroin, Lysergic Acid Diethylamide (LSD), 3,4-Methylenedioxymethamphetamine (MDMA / Ecstasy), Mescaline, Peyote, Psilocybin, Methaqualone (Quaalude), synthetic cathinones ("bath salts"), and Marijuana (Cannabis sativa L. extracts with > 0.3% delta-9-THC under federal law).
• Prescribing & Dispensing Rule: C-I substances cannot be prescribed, administered, or dispensed in standard pharmacy practice. They may only be acquired and utilized by DEA-registered researchers possessing an approved FDA Investigational New Drug (IND) protocol.

Schedule II (C-II)

• Statutory Finding: The drug has a high potential for abuse, has a currently accepted medical use in treatment in the United States (or accepted medical use with severe restrictions), and abuse may lead to severe psychological or physical dependence.
• Representative Opioids: Morphine, Oxycodone (OxyContin, Percocet, Roxicodone), Hydrocodone combination products (Norco, Vicodin, Lortab — rescheduled from C-III to C-II in 2014), Hydromorphone (Dilaudid), Fentanyl (Duragesic, Actiq, Sublimaze), Methadone (Dolophine), Oxymorphone (Opana), Meperidine (Demerol), Tapentadol (Nucynta), and Codeine single-entity products.
• Representative Stimulants: Amphetamine salts (Adderall), Dextroamphetamine (Dexedrine), Lisdexamfetamine (Vyvanse), Methylphenidate (Ritalin, Concerta), Dexmethylphenidate (Focalin), Methamphetamine (Desoxyn), and Cocaine (used topically as a local anesthetic/vasoconstrictor in mucous membrane surgery).
• Representative Sedatives/Depressants: Secobarbital (Seconal), Pentobarbital (Nembutal), Amobarbital (Amytal).

Schedule III (C-III)

• Statutory Finding: The drug has a potential for abuse less than substances in Schedules I and II, has a currently accepted medical use, and abuse may lead to moderate or low physical dependence or high psychological dependence.
• Representative Substances: Buprenorphine single-entity and combination products (Suboxone, Subutex, Zubsolv, Butrans), Ketamine (Ketalar), Anabolic Steroids (e.g., testosterone cypionate/enanthate, nandrolone, oxandrolone), Dronabinol oral gelatin capsules (Marinol), Butabarbital (Butisol), Benzphetamine (Didrex), and Phendimetrazine.
• Narcotic Combination Thresholds: Acetaminophen with Codeine (Tylenol #3, Tylenol #4), Aspirin with Codeine, and Empracet containing not more than 90 milligrams of codeine per dosage unit, combined with one or more active non-narcotic therapeutic ingredients in recognized therapeutic amounts.

Schedule IV (C-IV)

• Statutory Finding: The drug has a low potential for abuse relative to substances in Schedule III, has a currently accepted medical use, and abuse may lead to limited physical dependence or psychological dependence relative to C-III.
• Representative Benzodiazepines: Alprazolam (Xanax), Diazepam (Valium), Lorazepam (Ativan), Clonazepam (Klonopin), Temazepam (Restoril), Triazolam (Halcion), Midazolam (Versed), Chlordiazepoxide (Librium), Clobazam (Onfi), Oxazepam.
• Representative Sedatives / Non-Benzodiazepine Hypnotics ("Z-drugs"): Zolpidem (Ambien), Zaleplon (Sonata), Eszopiclone (Lunesta).
• Other Representative Agents: Phenobarbital, Carisoprodol (Soma), Tramadol (Ultram, Ultracet), Modafinil (Provigil), Armodafinil (Nuvigil), Phentermine (Adipex-P), Diethylpropion, Suvorexant (Belsomra), Lemborexant (Dayvigo), Eluxadoline (Viberzi).

Schedule V (C-V)

• Statutory Finding: The drug has a low potential for abuse relative to substances in Schedule IV, has a currently accepted medical use, and abuse may lead to more limited physical or psychological dependence liabilities.
• Representative Anticonvulsants / Neuropathic Agents: Pregabalin (Lyrica), Lacosamide (Vimpat), Brivaracetam (Briviact).
• Representative Antidiarrheals: Diphenoxylate with Atropine (Lomotil — containing not more than 2.5 mg of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit), Difenoxin/Atropine (Motofen — <= 0.5 mg difenoxin).
• Federal Narcotic Antitussive Thresholds: Liquid preparations containing not more than 200 milligrams of codeine per 100 milliliters or per 100 grams combined with one or more non-narcotic active medicinal ingredients (e.g., Promethazine with Codeine, Guaifenesin with Codeine [Robitussin AC, Cheratussin AC]).

2. Controlled Substance Labeling Symbols (21 CFR § 1302.03)

Under federal regulations (21 CFR § 1302.03), commercial containers of all controlled substances must prominently display a designated schedule symbol on the principal label:

• Symbols Required: C-I (or C-1), C-II (or C-2), C-III (or C-3), C-IV (or C-4), C-V (or C-5), or the schedule designation enclosed within the letter "C" (e.g., a large "C" with Roman numeral "II" inside).
• Size & Contrast: The symbol must be printed in large, prominent font with contrasting color to the background, positioned in the upper right quadrant of the principal display panel or adjacent to the established proprietary drug name.
• Exemptions: Commercial containers that are too small to accommodate the symbol (e.g., single-dose unit ampules) may display the symbol on the outer carton or carton packaging.

---

3. High-Yield Schedule Thresholds & Boundary Rules

On the MPJE, questions frequently test the precise mathematical dividing lines that separate one controlled schedule from another or distinguish controlled from non-controlled formulations:

A. Codeine Concentration Limits (C-II vs. C-III vs. C-V)

Exam Trap — Calculating Codeine Limits: If a liquid preparation contains 240 mg of codeine per 100 mL (2.4 mg/mL), it exceeds the Schedule V ceiling of 200 mg/100 mL. Because it is <= 1.8 g/100 mL (1,800 mg/100 mL), it falls into Schedule III. If a compound contains 2.0 grams of codeine per 100 mL, it exceeds the C-III limit and becomes Schedule II.

B. Dronabinol (Delta-9-THC) Dosage Form Divergence

• Schedule III (C-III): Dronabinol formulated in synthetic soft gelatin capsules in sesame oil (Marinol) is Schedule III because the oil vehicle makes parenteral abuse and rapid extraction difficult.
• Schedule II (C-II): Dronabinol formulated as an oral solution in 50% alcohol (Syndros) is Schedule II because liquid solutions pose a substantially higher risk of abuse, diversion, and vaporization.

C. Opium and Morphine Combination Ceilings

• Schedule III Opium Limit: Not more than 500 mg of opium per 100 mL or per 100 grams, and not more than 25 mg per dosage unit, with active non-narcotic ingredients (e.g., Paregoric).
• Schedule III Morphine Limit: Not more than 50 mg of morphine per 100 mL or per 100 grams with active non-narcotic ingredients.
• Schedule V Opium Limit: Not more than 100 mg of opium per 100 mL or per 100 grams (e.g., Kapectolin PG, Parepectolin).

---

4. Kentucky-Specific Controlled Substance Classifications

The Commonwealth of Kentucky exercises its Tenth Amendment police power to reclassify multiple substances into more restrictive schedules under Title 902 KAR Chapter 55. Candidates must memorize these state-specific classifications:

┌─────────────────────────────────────────────────────────────────────────────┐
│                     KENTUCKY-SPECIFIC CONTROLLED SUBSTANCES                 │
├─────────────────────┬───────────────────┬───────────────────┬───────────────┤
│ Drug Name           │ Federal Schedule  │ Kentucky Schedule │ Regulation    │
├─────────────────────┼───────────────────┼───────────────────┼───────────────┤
│ Gabapentin          │ Non-Controlled    │ Schedule V        │ 902 KAR 55:015│
│ (Neurontin, Gralise)│ (Legend Drug)     │ (Effective 2017)  │               │
├─────────────────────┼───────────────────┼───────────────────┼───────────────┤
│ Butalbital / APAP / │ Exempt Product    │ Schedule III      │ 902 KAR 55:045│
│ Caffeine (Fioricet) │ (Non-Controlled)  │ (ALL Butalbital)  │               │
├─────────────────────┼───────────────────┼───────────────────┼───────────────┤
│ Nalbuphine          │ Non-Controlled    │ Schedule IV       │ 902 KAR 55:015│
│ (Nubain)            │ (Legend Drug)     │                   │               │
├─────────────────────┼───────────────────┼───────────────────┼───────────────┤
│ Pentazocine (Talwin)│ Schedule IV       │ Schedule III      │ 902 KAR 55:015│
│                     │                   │ (upgraded)        │               │
├─────────────────────┼───────────────────┼───────────────────┼───────────────┤
│ Barbital, Methyl-   │ Schedule IV       │ Schedule III      │ 902 KAR 55:015│
│ phenobarbital,      │                   │ (upgraded)        │               │
│ Phenobarbital       │                   │                   │               │
├─────────────────────┼───────────────────┼───────────────────┼───────────────┤
│ Tianeptine          │ Unscheduled       │ Schedule I        │ 902 KAR 55:015│
│ ("gas station       │ (FDA: not a       │ (no medical use   │               │
│  heroin")           │  dietary suppl.)  │  in KY)           │               │
└─────────────────────┴───────────────────┴───────────────────┴───────────────┘

> **Citation Trap — the repealed schedule regulations.** Many MPJE prep sources still cite
> **902 KAR 55:020 (Schedule II), 55:025 (Schedule III), 55:030 (Schedule IV), and 55:035
> (Schedule V)**. Those four regulations were **repealed by 902 KAR 55:041** and consolidated
> into a single regulation, **902 KAR 55:015 (Schedules of controlled substances)**, most
> recently amended effective **3-12-2026**. If a study aid cites 55:020 for nalbuphine, it is
> working from a superseded source.

1. Gabapentin Reclassified as Schedule V (902 KAR 55:015)

• Effective Date: July 1, 2017.
• Rationale: Epidemic-level co-ingestion of gabapentin with opioids to potentiate euphoria, respiratory depression, and overdose lethality.
• Legal Impact in Kentucky:
  • Gabapentin prescriptions are subject to all Kentucky Schedule V rules: valid for a maximum of 6 months from the date of issue, with a maximum of 5 refills.
  • Every dispensing of gabapentin must be reported electronically to the KASPER PDMP within 1 business day.
  • Must be stored under controlled substance physical security rules (locked cabinet or dispersed).
  • Transfers between pharmacies are restricted to the one-time transfer rule (or real-time database limits) under 201 KAR 2:165.

2. All Butalbital Formulations Reclassified as Schedule III (902 KAR 55:045)

• The Federal Exemption Loophole: Under federal CSA rules (21 CFR § 1308.32), combination barbiturate products are exempt from scheduling if they contain a specific ratio of non-controlled analgesics (e.g., at least 70 mg of acetaminophen or 188 mg of aspirin per 15 mg of butalbital). Under this federal formula, Fioricet (butalbital 50 mg / acetaminophen 325 mg / caffeine 40 mg) is non-controlled federally, whereas Fiorinal (butalbital 50 mg / aspirin 325 mg / caffeine 40 mg) is Schedule III.
• The Kentucky Rule: Kentucky administrative regulation 902 KAR 55:045 explicitly rejects the federal exemption. In Kentucky, ALL butalbital-containing products (including Fioricet, Fioricet with Codeine, Fiorinal, and generic butalbital/APAP/caffeine) are Schedule III controlled substances.
• Legal Impact in Kentucky:
  • Written prescriptions must be executed on a Kentucky Security Prescription Blank (902 KAR 55:105).
  • Valid for a maximum of 6 months from the date of issue, with a maximum of 5 refills.
  • All dispensings are transmitted to KASPER.
  • Stored in a locked cabinet or dispersed throughout non-controlled inventory.

3. Nalbuphine (Nubain) Reclassified as Schedule IV (902 KAR 55:015)

• Federal Status: Nalbuphine is a synthetic opioid agonist-antagonist analgesic that is not scheduled under the federal CSA.
• Kentucky Status: Under 902 KAR 55:015, Kentucky classifies Nalbuphine as a Schedule IV controlled substance.
• Legal Impact in Kentucky: Subject to all C-IV dispensing constraints, 6-month / 5-refill maximums, security blank mandates, and KASPER reporting.

4. Pentazocine, Barbiturates and Tianeptine (902 KAR 55:015)

• Pentazocine (Talwin, Talwin NX): federal Schedule IV, but Kentucky designates it Schedule III. The Cabinet's stated rationale is pentazocine's significant abuse potential.
• Barbital, methylphenobarbital, and phenobarbital: federal Schedule IV, but Kentucky designates these derivatives of barbituric acid Schedule III. This is the single most-missed Kentucky upgrade: a phenobarbital 32.4 mg prescription is a C-III in Kentucky, so it must be written on a Kentucky security prescription blank and is capped at 5 refills / 6 months — the C-IV assumptions a candidate carries in from federal law produce the wrong answer.
• Tianeptine ("gas station heroin"): unscheduled federally, but Kentucky designates it Schedule I, meaning it has no dispensable medical use in the Commonwealth.

5. Non-Prescription (Exempt) Codeine Preparations — Kentucky PERMITS Them (KRS 218A.190)

This is the most frequently mis-taught point in Kentucky controlled substance law. Kentucky does not ban over-the-counter Schedule V codeine sales. Two provisions authorize them:

• 902 KAR 55:015, Section 6: a Schedule V controlled substance that is not a prescription drug under the FDCA "may be dispensed by a pharmacist without a prescription" to a retail purchaser if nine conditions are met, including a 240 cc / 48-hour ceiling on opium-containing preparations.
• KRS 218A.190 (Exempt codeine preparations): a codeine preparation may be sold without a prescription if it contains no more than 200 mg of codeine (or its salts) per 100 mL or per 100 g, contains additional non-narcotic medicinal ingredients, is sold in good faith as a medicine, is dispensed only by a pharmacist, is sold only to a purchaser 18 years of age or older, is not publicly displayed (kept behind the counter), and does not exceed 120 mL purchased by one person within any 48-hour period.

Exam Trap — do not "upgrade" Kentucky into a ban. Kentucky genuinely is stricter than federal law on gabapentin, nalbuphine, butalbital, pentazocine, and the barbiturates. That pattern tempts candidates to assume Kentucky also bans exempt codeine sales. It does not. What Kentucky adds is a statutory registry, a no-public-display rule, and a Cabinet veto over individual products. Employer policy frequently forbids these sales — but employer policy is not the law the MPJE is testing.

5. Comprehensive Federal vs. Kentucky Scheduling Master Reference

The following reference table summarizes the regulatory status of key drug classes across both jurisdictions:

6. Exam Watch: High-Yield MPJE Scenarios & Trap Warnings

Scenario 1: The Out-of-State Fioricet Prescription

Scenario: A patient presents a written prescription for Fioricet (butalbital 50 mg / APAP 325 mg / caffeine 40 mg) written by an Ohio physician on a standard Ohio prescription pad with "Refill x 11 (1 Year)." The patient notes that in Ohio, Fioricet is not a controlled substance. Legal Analysis: The pharmacist cannot dispense 11 refills or treat the order as non-controlled in Kentucky. Under 902 KAR 55:045, Fioricet is a Schedule III controlled substance in Kentucky. Consequently, it is subject to Kentucky's C-III limits: it expires in 6 months from the date of issue and may have no more than 5 refills. Furthermore, out-of-state prescribers must comply with Kentucky's security requirements or be verified under equivalent controlled substance rules.

Scenario 2: Refill Authorization for Gabapentin

Scenario: A patient calls a Louisville pharmacy requesting the 6th refill on a prescription for Gabapentin 300 mg capsules that was originally issued 4 months ago with "Refill PRN for 1 year." Legal Analysis: The pharmacist must refuse to process the 6th refill. Under 902 KAR 55:015, Gabapentin is a Schedule V controlled substance in Kentucky. Under KRS 218A.180, Schedule V controlled substances are limited to a maximum of 5 refills within a 6-month validity window. A "PRN" refill designation on a controlled substance in Kentucky is legally invalid beyond the statutory 5-refill / 6-month cap. The pharmacist must obtain a new prescription from the prescriber.

Scenario 3: Request for Non-Prescription Codeine Cough Syrup

Scenario: An adult patient with a severe cough presents to a Covington pharmacy on a Sunday evening requesting to purchase a 4 oz (120 mL) bottle of Cheratussin AC (guaifenesin 100 mg / codeine 10 mg per 5 mL). The patient provides a valid Kentucky driver's license showing they are 35 years old and offers to sign the pharmacy's exempt narcotic register. Legal Analysis: The sale is lawful, and the pharmacist personally must make it. Run the KRS 218A.190 checklist: the product is 10 mg/5 mL = 200 mg per 100 mL (at, not over, the ceiling); guaifenesin is an additional medicinal ingredient; the purchaser is over 18 with government photo ID; 120 mL does not exceed the 48-hour limit; and the syrup must be stored behind the counter rather than on open display. The pharmacist — not a technician or an intern — completes the transaction and enters the date, the purchaser's name and address, the preparation name, the quantity, and the dispenser's name in the separate registry required by KRS 218A.190(3). The sale must be a good-faith sale as medicine; if the pharmacist believes the request is for abuse or diversion, professional judgment (and corresponding responsibility) supports refusal even though the statutory elements are met. Trap: If the same patient returned the next day for a second 120 mL bottle, the second sale would exceed 120 mL per person per 48 hours and must be refused.